157 related articles for article (PubMed ID: 11029473)
1. Diabetic nephropathy--where next?
Phillips AO
QJM; 2000 Oct; 93(10):643-6. PubMed ID: 11029473
[No Abstract] [Full Text] [Related]
2. [The effect of angiotensin-converting enzyme inhibitors on the progression of chronic renal failure].
Bernadet-Monrozies P; Rostaing L; Kamar N; Durand D
Presse Med; 2002 Nov; 31(36):1714-20. PubMed ID: 12467154
[TBL] [Abstract][Full Text] [Related]
3. Diabetic nephropathy.
Wylie EC; Satchell SC
Clin Med (Lond); 2012 Oct; 12(5):480-2; quiz 483-5. PubMed ID: 23101153
[No Abstract] [Full Text] [Related]
4. Renal implications of angiotensin receptor blockers.
Hollenberg NK
Am J Hypertens; 2001 Jul; 14(7 Pt 2):237S-241S. PubMed ID: 11459212
[TBL] [Abstract][Full Text] [Related]
5. Diabetic nephropathy: where are we on the journey from pathophysiology to treatment?
Gallagher H; Suckling RJ
Diabetes Obes Metab; 2016 Jul; 18(7):641-7. PubMed ID: 26743887
[TBL] [Abstract][Full Text] [Related]
6. Best practice for hypertensive patients with kidney disease.
de Zeeuw D
Hosp Med; 2003 Feb; 64(2):96-100. PubMed ID: 12619337
[TBL] [Abstract][Full Text] [Related]
7. Management of diabetic nephropathy.
Foggensteiner L; Mulroy S; Firth J
J R Soc Med; 2001 May; 94(5):210-7. PubMed ID: 11385086
[No Abstract] [Full Text] [Related]
8. Angiotensin II (AT(1)) receptor antagonists, diabetes, and nephropathy: do differences between the renal and systemic circulations explain the outcomes observed with ARBs and ACE inhibitors?
Giles TD; Sander GE
Am J Geriatr Cardiol; 2002; 11(1):62-5. PubMed ID: 11773721
[No Abstract] [Full Text] [Related]
9. [Prevention and remission of diabetic nephropathy].
Sugimoto T; Nakamura Y; Makino H
Nihon Rinsho; 2003 Jul; 61(7):1167-71. PubMed ID: 12877079
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic controversies in hypertension management: angiotensin converting enzyme (ACE) inhibitors or angiotensin receptor blockers for diabetic nephropathy? A case for ACE inhibitors.
Crook ED; Preddie DC
Ethn Dis; 2002; 12(4):S3-49-52. PubMed ID: 12477155
[TBL] [Abstract][Full Text] [Related]
11. [Treatment recommendations for various stages in diabetic nephropathy].
Takane H; Suzuki H
Nihon Rinsho; 2005 Jun; 63 Suppl 6():379-83. PubMed ID: 15999738
[No Abstract] [Full Text] [Related]
12. [Can progression to terminal renal insufficiency be avoided in diabetic nephropathy?].
Luño J; Valderrábano F
An Med Interna; 1998 Nov; 15(11):567-71. PubMed ID: 9882851
[No Abstract] [Full Text] [Related]
13. The role of angiotensin receptor blockers in diabetic nephropathy.
Sharma AM; Weir MR
Postgrad Med; 2011 May; 123(3):109-21. PubMed ID: 21566421
[TBL] [Abstract][Full Text] [Related]
14. [Diabetic nephropathy: natural history and therapeutic interventions].
Scheen AJ
Rev Med Liege; 1993 Dec; 48(12):645-58. PubMed ID: 8310199
[No Abstract] [Full Text] [Related]
15. Diabetic nephropathy: changing concepts of pathogenesis and treatment.
Bell DS
Am J Med Sci; 1991 Mar; 301(3):195-200. PubMed ID: 2000893
[TBL] [Abstract][Full Text] [Related]
16. Preserving the diabetic kidney.
Poirier SJ
J Fam Pract; 1998 Jan; 46(1):21-7. PubMed ID: 9451365
[TBL] [Abstract][Full Text] [Related]
17. [Angiotensin II type-1 receptor antagonists and diabetes mellitus].
Schnack C; Schernthaner G
Wien Med Wochenschr; 2001; 151(7-8):165-8. PubMed ID: 11450165
[TBL] [Abstract][Full Text] [Related]
18. Diabetic nephropathy: common questions.
Thorp ML
Am Fam Physician; 2005 Jul; 72(1):96-9. PubMed ID: 16035688
[TBL] [Abstract][Full Text] [Related]
19. Microalbuminuria in diabetes mellitus.
Tobe SW; McFarlane PA; Naimark DM
CMAJ; 2002 Sep; 167(5):499-503. PubMed ID: 12240818
[No Abstract] [Full Text] [Related]
20. Renoprotective effects of renin-angiotensin-system inhibitors.
de Zeeuw D; Lewis EJ; Remuzzi G; Brenner BM; Cooper ME
Lancet; 2006 Mar; 367(9514):899-900; author reply 900-2. PubMed ID: 16546533
[No Abstract] [Full Text] [Related]
[Next] [New Search]
